Inclusion Criteria:  Subject must be ≥18 years of age. Subject must have pathologically documented, locally advanced or metastatic KRASG12C NSCLC (not amenable to curative surgery) that has progressed on prior standard therapies (no more than 3 prior lines of therapies are allowed)  Exclusion Criteria  Primary central nervous system (CNS) tumors Known or suspected leptomeningeal or brain metastases or spinal cord compression Clinically significant cardiac disease Known impairment of GI function that would alter the absorption Active autoimmune disease requiring systemic treatment within past 2 years History of severe allergic reactions to any of the study intervention components Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment. Prior therapy with KRASG12C inhibitor and/or SHP2 inhibitor